ACOR - Acorda Therapeutics Continues To Maneuver For A Turnaround

• Acorda Therapeutics continues to maneuver to set up for a potential turnaround in the coming years.
• The company recently announced a commercial partnership with Esteve Pharmaceuticals for INBRIJA in Spain. I expect additional European and Ex-U.S. partnerships are on the docket.
• Acorda was able to remove their debt that was due in 2021. Now, with that overhang removed, any progress made should be reflected in the share price.
• I update my plan for trading Acorda over the remainder of 2021 as we wait for the remaining quarterly earnings.

For further details see: